Spruce Biosciences, Inc. Stock Price, News & Analysis

Spruce Biosciences (Nasdaq: SPRB) reported progress in its CAHmelia-203 study for adult classic congenital adrenal hyperplasia (CAH), achieving 25% enrollment and expects topline data by H2 2023. The company amended its debt facility with Silicon Valley Bank for a $10 million credit line, reducing interest rates. R&D expenses rose to $8.5 million, while total operating expenses increased to $11.7 million, resulting in a net loss of $11.8 million for Q1 2022. The patent portfolio for tildacerfont has also expanded, enhancing market exclusivity.

Spruce Biosciences (NASDAQ: SPRB) announced its participation in two upcoming investor conferences in May 2022. The first event is the RBC Capital Markets Global Healthcare Conference on May 17-18, featuring a fireside chat on May 17 at 10:00 a.m. ET. The second event is the H.C. Wainwright Global Investment Conference from May 23-26, with a company presentation on May 25 at 4:00 p.m. ET. Interested investors can access webcasts via the company’s investor relations website. Spruce focuses on therapies for rare endocrine disorders.

Spruce Biosciences, Inc. (NASDAQ: SPRB) has appointed Libbie Mansell, Ph.D., M.B.A., R.A.C., as its Chief Regulatory and Quality Officer. Dr. Mansell will lead global regulatory affairs and quality strategy as the company advances its drug tildacerfont for rare endocrine disorders, including congenital adrenal hyperplasia and polycystic ovary syndrome. With over 30 years of experience in regulatory affairs, she aims to enhance Spruce's pipeline of treatments for significant unmet medical needs. CEO Javier Szwarcberg highlights her extensive expertise as a critical addition to the team.

Spruce Biosciences, Inc. (Nasdaq: SPRB) reports its fourth quarter and annual financial results for 2021, highlighting progress in developing treatments for rare endocrine disorders. The company anticipates topline safety data from its Phase 2 Pediatric Classic CAH study by 1H 2023. As of December 31, 2021, Spruce had cash and investments of $121.4 million, expected to fund operations into Q2 2024. R&D expenses increased to $30.7 million from $23.9 million in 2020. The net loss for 2021 was $42.3 million, compared to $29.5 million the previous year.

Spruce Biosciences, Inc. (NASDAQ: SPRB) has appointed Dr. Will Charlton as Chief Medical Officer following the departure of Dr. Rosh Dias. Dr. Charlton, with over 15 years in clinical research and experience in rare disease drug development, will lead Spruce's clinical strategies, particularly focusing on tildacerfont, aimed at treating classic congenital adrenal hyperplasia and polycystic ovary syndrome.

CEO Javier Szwarcberg expressed confidence in Dr. Charlton's expertise, anticipating significant advancements in therapies for rare endocrine disorders, which have seen no new treatments in nearly 50 years.

Spruce Biosciences (NASDAQ: SPRB), a late-stage biopharmaceutical company, announced its participation in two virtual investor conferences in March 2022. The Cowen 42nd Annual Health Care Conference will occur from March 7-9, featuring a company presentation on March 9 at 11:10 a.m. ET. The Oppenheimer 32nd Annual Healthcare Conference will take place from March 15-17, with a fireside chat on March 16 at 8:00 a.m. ET. Webcasts of these events will be accessible on the company's investor relations website.

Spruce Biosciences, Inc. (NASDAQ: SPRB) announces participation in the SVB Leerink 11th Annual Global Healthcare Conference on February 17, 2022, at 5:00 PM EST. CEO Javier Szwarcberg and CFO Samir Gharib will engage in a virtual fireside chat. This company focuses on developing therapies for rare endocrine disorders, particularly its candidate tildacerfont for classic congenital adrenal hyperplasia (CAH) and polycystic ovary syndrome (PCOS). Interested parties can access the live webcast on the company's investor relations website, with an archived replay available for 30 days.

Spruce Biosciences, Inc. (NASDAQ: SPRB) announced updates on its CAHmelia clinical program for tildacerfont, targeting adult classic congenital adrenal hyperplasia. The company plans to expand its global trial sites by up to 50, enhancing recruitment and optimizing study design for CAHmelia-203 and CAHmelia-204. Strategic prioritization extends its cash runway into Q2 2024, with topline data expected in 2H 2023 and 2H 2024 respectively. Additionally, a Phase 2 trial for pediatric CAH has been initiated, while a PCOS program is also underway.

Spruce Biosciences has appointed Dr. Javier Szwarcberg as CEO and promoted Samir Gharib to President, who will also remain CFO. Dr. Szwarcberg brings over 18 years of experience, having led 22 clinical trials and achieved 4 drug approvals. His focus will be on advancing tildacerfont, a potential first non-steroidal therapy for classic congenital adrenal hyperplasia (CAH). Gharib's promotion aims to leverage his business acumen for the company’s growth. Szwarcberg will receive stock options as part of his inducement award.